Revenue · 2023–2025
Telix Pharmaceuticals revenue
$804M+55.6% · FY2025
Telix Pharmaceuticals (TLX) reported $804M in revenue for fiscal 2025, +55.6% year on year.
Revenue — Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2023–2025 compound annual growth +55.4%
Figures are reported under IFRS, in US dollars.
Revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Telix Pharmaceuticals revenue |url=https://companiesranked.com/en/company/telix-pharmaceuticals/revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Telix Pharmaceuticals revenue. CompaniesRanked. https://companiesranked.com/en/company/telix-pharmaceuticals/revenueBibTeX
@misc{companiesranked-en-company-telix-pharmaceuticals-revenue-2026,
author = {{CompaniesRanked}},
title = {{Telix Pharmaceuticals revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/telix-pharmaceuticals/revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001628280-26-009943 · February 20, 2026
{{cite web |title=Telix Pharmaceuticals revenue — 20-F (0001628280-26-009943) |url=https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-20}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.